China (Mainland)
Pharmaceutical Raw Materials Anti Diabetes Drug Empagliflozin Manufacturer 864070-44-0 CAS NO.864070-44-0
- Min.Order: 0 Gram
- Payment Terms: L/C
- Product Details
Keywords
- 99% Empagliflozin
- 99% Empagliflozin
- 99% Empagliflozin
Quick Details
- ProName: Pharmaceutical Raw Materials Anti Diab...
- CasNo: 864070-44-0
- Molecular Formula: C23H27ClO7
- Appearance: white crystalline powder
- Application: use in chemical
- DeliveryTime: within a week
- PackAge: bags
- Port: Shanghai
- ProductionCapacity: 12 Kilogram/Day
- Purity: 99%
- Storage: Kept in a well-closed, light-resistant...
- Transportation: by sea or express
- LimitNum: 0 Gram
- Moisture Content: 0.1%
- Impurity: 0.05%
- Water content: 0%
Superiority
Details
Empagliflozin Description
Empagliflozin (trade name Jardiance) is a drug of the gliflozin class, approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company.
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine.
Empagliflozin is a potent SGLT-2 inhibitor and has a high degree of selectivity over SGLT-1, 4, 5 and 6 than other reported SGLT-2 inhibitors. When tested with a panel of human cell lines over-expressed SGLT-1, 2, 4, 5 and 6,
Empagliflozin treatment competitively bind to SGLT-2 over glucose at low dose .
In human proximal tublular cell (PTC) cell line HK2 cells, Empagliflozin treatment for 72 h inhibits the expression of SGLT-2 which in turn reversed high glucose induced TLR4 expression, NF-κB binding, IL-6 secretion, AP-1 binding and CIV expression .
Empagliflozin Basic Information
| Name | Empagliflozin |
| Synonyms | BI 10773; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol |
| Molecular Formula | C23H27ClO7 |
| Molecular Weight | 450.91 |
| CAS Registry Number | 864070-44-0 |
|
|
||